242 related articles for article (PubMed ID: 31498563)
1. Perinatal outcomes following maternal pre-exposure prophylaxis (PrEP) use during pregnancy: results from a large PrEP implementation program in Kenya.
Dettinger JC; Kinuthia J; Pintye J; Abuna F; Begnel E; Mugwanya K; Sila J; Lagat H; Baeten JM; John-Stewart G
J Int AIDS Soc; 2019 Sep; 22(9):e25378. PubMed ID: 31498563
[TBL] [Abstract][Full Text] [Related]
2. Pre-exposure prophylaxis uptake and early continuation among pregnant and post-partum women within maternal and child health clinics in Kenya: results from an implementation programme.
Kinuthia J; Pintye J; Abuna F; Mugwanya KK; Lagat H; Onyango D; Begnel E; Dettinger J; Baeten JM; John-Stewart G;
Lancet HIV; 2020 Jan; 7(1):e38-e48. PubMed ID: 31813837
[TBL] [Abstract][Full Text] [Related]
3. Integrating preexposure prophylaxis delivery in routine family planning clinics: A feasibility programmatic evaluation in Kenya.
Mugwanya KK; Pintye J; Kinuthia J; Abuna F; Lagat H; Begnel ER; Dettinger JC; John-Stewart G; Baeten JM;
PLoS Med; 2019 Sep; 16(9):e1002885. PubMed ID: 31479452
[TBL] [Abstract][Full Text] [Related]
4. Emerging evidence from a systematic review of safety of pre-exposure prophylaxis for pregnant and postpartum women: where are we now and where are we heading?
Joseph Davey DL; Pintye J; Baeten JM; Aldrovandi G; Baggaley R; Bekker LG; Celum C; Chi BH; Coates TJ; Haberer JE; Heffron R; Kinuthia J; Matthews LT; McIntyre J; Moodley D; Mofenson LM; Mugo N; Myer L; Mujugira A; Shoptaw S; Stranix-Chibanda L; John-Stewart G;
J Int AIDS Soc; 2020 Jan; 23(1):e25426. PubMed ID: 31912985
[TBL] [Abstract][Full Text] [Related]
5. Maternal Tenofovir Disoproxil Fumarate Use in Pregnancy and Growth Outcomes among HIV-Exposed Uninfected Infants in Kenya.
Pintye J; Langat A; Singa B; Kinuthia J; Odeny B; Katana A; Nganga L; John-Stewart G; McGrath CJ
Infect Dis Obstet Gynecol; 2015; 2015():276851. PubMed ID: 26823647
[TBL] [Abstract][Full Text] [Related]
6. Risk-based versus universal PrEP delivery during pregnancy: a cluster randomized trial in Western Kenya from 2018 to 2019.
Kinuthia J; Dettinger JC; Stern J; Ngumbau N; Ochieng B; Gómez L; Abuna F; Watoyi S; Marwa M; Odinga D; Wagner AD; Richardson BA; Pintye J; Baeten JM; John-Stewart G
J Int AIDS Soc; 2023 Feb; 26(2):e26061. PubMed ID: 36807505
[TBL] [Abstract][Full Text] [Related]
7. Integration of postpartum healthcare services for HIV-infected women and their infants in South Africa: A randomised controlled trial.
Myer L; Phillips TK; Zerbe A; Brittain K; Lesosky M; Hsiao NY; Remien RH; Mellins CA; McIntyre JA; Abrams EJ
PLoS Med; 2018 Mar; 15(3):e1002547. PubMed ID: 29601570
[TBL] [Abstract][Full Text] [Related]
8. PrEP Implementation for Mothers in Antenatal Care (PrIMA): study protocol of a cluster randomised trial.
Dettinger JC; Kinuthia J; Pintye J; Mwongeli N; Gómez L; Richardson BA; Barnabas R; Wagner AD; O'Malley G; Baeten JM; John-Stewart G
BMJ Open; 2019 Mar; 9(3):e025122. PubMed ID: 30850409
[TBL] [Abstract][Full Text] [Related]
9. Evolving treatment implementation among HIV-infected pregnant women and their partners: results from a national surveillance study in Italy, 2001-2015.
Floridia M; Frisina V; Ravizza M; Marconi AM; Pinnetti C; Cetin I; Sansone M; Molinari A; Cervi F; Meloni A; Luzi K; Masuelli G; Tamburrini E;
J Glob Health; 2017 Jun; 7(1):010407. PubMed ID: 28567279
[TBL] [Abstract][Full Text] [Related]
10. Pregnancy and neonatal safety outcomes of timing of initiation of daily oral tenofovir disoproxil fumarate and emtricitabine pre-exposure prophylaxis for HIV prevention (CAP016): an open-label, randomised, non-inferiority trial.
Moodley D; Lombard C; Govender V; Naidoo M; Desmond AC; Naidoo K; Mhlongo O; Sebitloane M; Newell ML; Clark R; Rooney JF; Gray G;
Lancet HIV; 2023 Mar; 10(3):e154-e163. PubMed ID: 36746169
[TBL] [Abstract][Full Text] [Related]
11. HIV-Uninfected Kenyan Adolescent and Young Women Share Perspectives on Using Pre-Exposure Prophylaxis During Pregnancy.
Pintye J; Beima-Sofie KM; Makabong'O PA; Njoroge A; Trinidad SB; Heffron RA; Baeten JM; Celum C; Matemo D; Kinuthia J; Kelley MC; John-Stewart GC
AIDS Patient Care STDS; 2018 Dec; 32(12):538-544. PubMed ID: 30036072
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal adherence to maternal antiretroviral therapy and infant Nevirapine prophylaxis from 6 weeks to 18 months postpartum amongst a cohort of mothers and infants in South Africa.
Larsen A; Magasana V; Dinh TH; Ngandu N; Lombard C; Cheyip M; Ayalew K; Chirinda W; Kindra G; Jackson D; Goga A
BMC Infect Dis; 2019 Sep; 19(Suppl 1):789. PubMed ID: 31526366
[TBL] [Abstract][Full Text] [Related]
13. Brief Report: Integration of PrEP Services Into Routine Antenatal and Postnatal Care: Experiences From an Implementation Program in Western Kenya.
Pintye J; Kinuthia J; Roberts DA; Wagner AD; Mugwanya K; Abuna F; Lagat H; Owiti G; Levin CE; Barnabas RV; Baeten JM; John-Stewart G
J Acquir Immune Defic Syndr; 2018 Dec; 79(5):590-595. PubMed ID: 30204720
[TBL] [Abstract][Full Text] [Related]
14. Pregnancy outcomes and infant growth among babies with in-utero exposure to tenofovir-based preexposure prophylaxis for HIV prevention.
Heffron R; Mugo N; Hong T; Celum C; Marzinke MA; Ngure K; Asiimwe S; Katabira E; Bukusi EA; Odoyo J; Tindimwebwa E; Bulya N; Baeten JM;
AIDS; 2018 Jul; 32(12):1707-1713. PubMed ID: 30001244
[TBL] [Abstract][Full Text] [Related]
15. Two-Way Short Message Service (SMS) Communication May Increase Pre-Exposure Prophylaxis Continuation and Adherence Among Pregnant and Postpartum Women in Kenya.
Pintye J; Rogers Z; Kinuthia J; Mugwanya KK; Abuna F; Lagat H; Sila J; Kemunto V; Baeten JM; John-Stewart G; Unger JA
Glob Health Sci Pract; 2020 Mar; 8(1):55-67. PubMed ID: 32139420
[TBL] [Abstract][Full Text] [Related]
16. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.
Gibb DM; Kizito H; Russell EC; Chidziva E; Zalwango E; Nalumenya R; Spyer M; Tumukunde D; Nathoo K; Munderi P; Kyomugisha H; Hakim J; Grosskurth H; Gilks CF; Walker AS; Musoke P;
PLoS Med; 2012; 9(5):e1001217. PubMed ID: 22615543
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
Sturt AS; Dokubo EK; Sint TT
Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
[TBL] [Abstract][Full Text] [Related]
18. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.
; de Vincenzi I
Lancet Infect Dis; 2011 Mar; 11(3):171-80. PubMed ID: 21237718
[TBL] [Abstract][Full Text] [Related]
19. Early pre-exposure prophylaxis (PrEP) initiation and continuation among pregnant and postpartum women in antenatal care in Cape Town, South Africa.
Joseph Davey DL; Mvududu R; Mashele N; Lesosky M; Khadka N; Bekker LG; Gorbach P; Coates TJ; Myer L
J Int AIDS Soc; 2022 Feb; 25(2):e25866. PubMed ID: 35138678
[TBL] [Abstract][Full Text] [Related]
20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
